Premium
Plasma galectin‐3 levels do not differ in systemic lupus erythematosus patients
Author(s) -
Zhao ChanNa,
Mao YanMei,
Liu LiNa,
Wu Qian,
Dan YiLin,
Pan HaiFeng
Publication year - 2019
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.13677
Subject(s) - medicine , lupus nephritis , plasma levels , significant difference , immune system , nephritis , endocrinology , lupus erythematosus , globulin , immunology , gastroenterology , antibody , disease
Objective To investigate the plasma galectin‐3 levels in systemic lupus erythematosus (SLE) patients and its relations with clinical and laboratory features. Methods A total of 180 subjects with 90 patients with SLE (8 male, 82 female, mean age 37.86 ± 13.98 years) and 90 healthy controls (8 male, 82 female, mean age 36.54 ± 10.89 years) were included. Plasma galectin‐3 levels were detected by enzyme‐linked immunosorbent assay (ELISA). Results There was no significant difference in age and gender distribution between SLE patients and healthy controls (both P > .05). Plasma galectin‐3 level was not significantly different between SLE patients and controls ( P = .982) ( P > .05). No significant difference was found regarding galectin‐3 levels between SLE with nephritis and those without nephritis ( P > .05); no significant difference was found between less active SLE and more active SLE ( P > .05). Galectin‐3 levels were inversely related to immune globulin M ( r = −.303, P < .05), while no significant correlation between galectin‐3 levels and other quantitative laboratory parameters were observed (all P > .05). Conclusions In summary, plasma galectin‐3 level was not significantly different between SLE patients and controls ( P = .982). Further studies are needed to elucidate the role of galectin‐3 in SLE.